Our umbrella review highlights the significant role of [18F]FES PET/CT in breast cancer management, providing a non-invasive method to assess functional ER expression, explore its heterogeneity across primary and metastatic sites, and predict response to endocrine therapy. This evidence concerns the gene ESR1 and breast carcinoma.